WALTHAM, Mass., May 22, 2020 – Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced the upcoming virtual presentation on the development of novel therapeutics focused on treating Central Nervous System (CNS) indications via the gut-brain axis at the American Society of Clinical Psychopharmacology (ASCP) 2020 Annual Meeting being held May 29-30, 2020.

Virtual Presentation Details:

Title: Harnessing the gut-brain axis to develop novel Central Nervous System (CNS) therapeutics to improve the quality of life for people with CNS diseases and disorders

Presenter: David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics

Session Title: Pharmaceutical Pipeline Session

Date and Time: Saturday, May 30, 2020 from 4:25-4:35 PM ET

About Axial Biotherapeutics

Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of the central nervous system (CNS) and other gut-derived diseases. The Company has built a pipeline of novel small molecules with lead programs to address the significant unmet patient needs associated with Autism Spectrum Disorder (ASD) and Parkinson’s Disease (PD).

Investor Contact:

Julie Seidel
Stern Investor Relations
(212) 362-1200